Is the price fair?
What ANAB's price assumes
AnaptysBio, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 4.56× revenue.
4.56
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.26%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +47%
Growth the price implies · The price pays for +47% free cash flow growth a year for a decade; revenue has grown +179% a year over the last three.
- Price / book
- 83.2
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 83.2
- Free cash flow, trailing twelve months
- $4.4M
- Market capitalisation
- $1.67B
- 3-year revenue growth
- +179%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #102 of 145 by Smart Score